AR065075A1 - Vectores para la expresion multiple de genes - Google Patents

Vectores para la expresion multiple de genes

Info

Publication number
AR065075A1
AR065075A1 ARP080100356A ARP080100356A AR065075A1 AR 065075 A1 AR065075 A1 AR 065075A1 AR P080100356 A ARP080100356 A AR P080100356A AR P080100356 A ARP080100356 A AR P080100356A AR 065075 A1 AR065075 A1 AR 065075A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
acid molecule
vector
polypeptide
homology percentage
Prior art date
Application number
ARP080100356A
Other languages
English (en)
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of AR065075A1 publication Critical patent/AR065075A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Vector para la expresion de una primera o segunda molécula de ácido nucleico que exhiben un porcentaje de homología de aproximadamente 80% o más de 80% sobre una porcion de 40 o más nucleotidos continuos y donde dicha primera molécula de ácido nucleico y/o dicha segunda molécula de ácido nucleico se modifica de tal manera de reducir dicho porcentaje de homología a menos de 75%. También se relaciona con una molécula sustancialmente aislada de ácido nucleico que comprende una secuencia de nucleotidos tal como se define en cualesquiera de las SEC ID N°:9-15 y 66-69, también provee una célula huésped y una composicion farmacéutica que comprende dicha molécula de ácido nucleico o vector así como también su uso, para fines terapéuticos o preventivos. Reivindicacion 1: Un vector que comprende por lo menos a una primera molécula de ácido nucleico que codifica a un primer polipéptido y a una segunda molécula de ácido nucleico que codifica a un segundo polipéptido donde: dicha primera y segunda molécula de ácido nucleico se obtienen respectivamente de una primera y una segunda secuencia nativa de ácido nucleico, las que exhiben un porcentaje de homología de aproximadamente 80% o más de 80% sobre una porcion de 40 o más nucleotidos continuos, y dicha primera molécula de ácido nucleico y/o dicha segunda molécula de ácido, nucleico comprendidas en el vector se modifica de tal manera de reducir dicho, porcentaje de homología a menos del 75%. Reivindicacion 6: El vector de acuerdo a cualquiera de las reivindicaciones 1 a 5, donde el vector es un vector de adenovirus. Reivindicacion 12: El vector de acuerdo a la reivindicacion 11, donde dicho organismo es un papilomavirus y cada primera y segunda molécula de ácido nucleico codifica a un polipéptido de papilomavirus.
ARP080100356A 2007-05-15 2008-01-29 Vectores para la expresion multiple de genes AR065075A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07360019 2007-05-15

Publications (1)

Publication Number Publication Date
AR065075A1 true AR065075A1 (es) 2009-05-13

Family

ID=39522406

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100356A AR065075A1 (es) 2007-05-15 2008-01-29 Vectores para la expresion multiple de genes

Country Status (17)

Country Link
US (1) US8337859B2 (es)
EP (1) EP2162544B1 (es)
JP (1) JP5474767B2 (es)
KR (1) KR101514473B1 (es)
CN (1) CN101688223B (es)
AR (1) AR065075A1 (es)
AU (1) AU2008250520B2 (es)
BR (1) BRPI0810305A2 (es)
CA (1) CA2686772C (es)
ES (1) ES2416361T3 (es)
HK (1) HK1135731A1 (es)
IL (1) IL201963A (es)
MX (1) MX2009012272A (es)
PE (1) PE20090483A1 (es)
RU (1) RU2462513C2 (es)
TW (1) TW200844231A (es)
WO (1) WO2008138648A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008138649A2 (en) 2007-05-15 2008-11-20 Transgene S.A. Signaling peptides
US9206440B2 (en) * 2009-01-23 2015-12-08 Roger Williams Hospital Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
US9393299B2 (en) * 2009-08-07 2016-07-19 Transgene S.A. Composition for treating HBV infection
EP2558116B2 (de) * 2010-04-16 2020-01-08 General Vectors GmbH Mittel zur lokalen behandlung von zervixdysplasien
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
AU2012245395A1 (en) * 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
US9492526B2 (en) * 2012-01-24 2016-11-15 Sanford Health Polynucleotides for treating oncogenic viral polypeptide positive tumors
EP2958994B1 (en) 2013-02-21 2019-05-29 Turnstone Limited Partnership Vaccine composition
AU2015332524A1 (en) * 2014-10-14 2017-06-01 The Trustees Of The University Of Pennsylvania Recombinant Listeria vaccine strains and methods of using the same in cancer immunotherapy
ES2634802B1 (es) * 2016-03-28 2018-07-03 Victor Manuel GALVEZ JEREZ Molécula de ácido nucleico y método para modificar de forma bialélica un gen diana o locus presente en el material genético de una célula
WO2017192418A1 (en) * 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
EP3461497A1 (en) * 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
KR20210093303A (ko) * 2018-11-21 2021-07-27 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 아데노바이러스 및 아데노바이러스의 사용 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
ATE285410T1 (de) * 1997-06-30 2005-01-15 Nippon Kayaku Kk Naphthyridinderivate oder salze davon
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
US7001995B1 (en) * 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
PT1212358E (pt) * 1999-08-25 2005-04-29 Merck & Co Inc Genes sinteticos de papilomavirus humano
CA2457890A1 (en) 2001-08-23 2003-03-06 Merck & Co., Inc. Vaccine using papillomavirus e proteins delivered by viral vector
CA2481799C (en) * 2002-05-16 2014-01-28 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
PE20081723A1 (es) * 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus

Also Published As

Publication number Publication date
IL201963A (en) 2013-09-30
ES2416361T3 (es) 2013-07-31
HK1135731A1 (en) 2010-06-11
CA2686772A1 (en) 2008-11-20
US8337859B2 (en) 2012-12-25
AU2008250520B2 (en) 2013-10-31
TW200844231A (en) 2008-11-16
AU2008250520A1 (en) 2008-11-20
EP2162544A1 (en) 2010-03-17
IL201963A0 (en) 2011-08-01
RU2009144898A (ru) 2011-06-20
MX2009012272A (es) 2009-12-01
JP2010526547A (ja) 2010-08-05
KR101514473B1 (ko) 2015-04-22
CN101688223B (zh) 2013-07-31
RU2462513C2 (ru) 2012-09-27
BRPI0810305A2 (pt) 2018-07-10
WO2008138648A1 (en) 2008-11-20
US20100303838A1 (en) 2010-12-02
CA2686772C (en) 2015-03-24
JP5474767B2 (ja) 2014-04-16
PE20090483A1 (es) 2009-05-20
KR20100019432A (ko) 2010-02-18
CN101688223A (zh) 2010-03-31
EP2162544B1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
AR065075A1 (es) Vectores para la expresion multiple de genes
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
AR065350A1 (es) Moleculas de acido nucleicos que codifican una alternanosucrasa truncada
GB201201178D0 (en) Novel enzymes
MX2020003092A (es) Vectores de adn no integrantes para la modificacion genetica de celulas.
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
CR20200236A (es) Synpiii, un promotor para la expresión específica de genes en el epitelio pigmentario retiniano
MY160897A (en) Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
WO2015051199A3 (en) Modified pseudomonas exotoxin a
AR090417A1 (es) Plantas resistentes al glifosato y metodos asociados
BRPI0806578A8 (pt) Promotores de lactococcus e usos dos mesmos
MX2012015142A (es) Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo.
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
MY176331A (en) Carbohydrate degrading polypeptide and uses thereof
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
NZ592082A (en) Promoters for recombinant viral expression
ES2543203T3 (es) Grupo de genes NRPS-PKS, su manipulación y su utilidad
MX2020005458A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
AR072022A1 (es) Genes involucrados en biosintesis de flavonoides en plantas
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
BRPI0806252B8 (pt) molécula de ácido nucléico de promotor, vetor recombinante, célula de hospedeiro e método de expressão de gene alvo
EA201590794A1 (ru) Рекомбинантные нейротоксины clostridium botulinum
PH12015500771A1 (en) Novel fc gamma receptor iib variants

Legal Events

Date Code Title Description
FA Abandonment or withdrawal